Good day, and thank you for standing by. Welcome to the Arbutus Third Quarter Corporate and Financial Update Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to Lisa Caperelli. Please go ahead.

Thank you, Brianna. Good morning, everyone, and thank you for joining Arbutus' third quarter 2023 financial results and corporate update call. Joining me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; David Hastings, Chief Financial Officer; Michael J. McElhaugh, Chief Operating Officer Dr. Mike Sofia, Chief Scientific Officer; and Dr. Karen Sims, Chief Medical Officer. Bill will begin with a corporate update, followed by Dave Hastings who will provide a review of the company's third quarter 2023 financial results. After our prepared remarks, we will open the call for Q&A. Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements, which are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our most recent annual report on Form 10-K, our quarterly report on Form 10-Q, which will be filed later today and from time to time in our other documents filed with the SEC. With that, I'll turn the call over to Bill Collier. Bill?

Good morning everyone and thank you very much for joining us today. As you likely saw in addition to reporting our third quarter results earlier this morning, we also announced that I will be retiring at the end of the year. I’ll speak more about that shortly, but first let's discuss our results. At Arbutus, we remain committed to our goal of developing a functional cure for patients with chronic hepatitis B virus by advancing the development of our clinical assets that can be combined to create a curative treatment regimen. Over the last few months, we've optimized our pipeline, including the discontinuation of our coronavirus research programs and our oral RNA destabilizer. This allows us to sharpen our focus and resources on our most promising clinical programs, imdusiran and AB-101, both of which are expected to have data readouts next year. As a result of this pipeline prioritization, we are also announcing today the difficult decision to streamline our organization by reducing our workforce by 24%. We want to underscore how grateful we are to all of our employees, especially those departing the organization for their dedication and passion in developing novel therapeutics for viral diseases at Arbutus. And while these changes primarily impact our research function, we have maintained a group of research scientists as we remain committed to continuing discovery research in chronic HBV. Now we know that changes that impact our people are not easy, and we're committed to providing those employees with support as they transition to their next roles. At the same time, we're confident that Arbutus remains positively positioned for the future. Now I'd like to provide some updates on the continued progress that we're making across our pipeline. With more than 290 million people worldwide chronically infected with HBV, and with current…

Thanks, Bill, and good morning, everybody. We ended the third quarter of 2023 with approximately $145 million of cash, cash equivalents of investments, compared to approximately $184 million as of December 31st, 2022. During the nine months ended September 30th, 2023, we received approximately $26 million of net proceeds from the issuance of common shares under Arbutus' at-the-market offering program. These cash inflows were offset by approximately $69 million of cash used in operations. As Bill mentioned, today we announced that we reduced our workforce by 24%. Importantly, we have maintained a discovery research capability in HBV and continue to believe we have the people necessary to advance our clinical-stage HBV pipeline. With this reduction in workforce, we will incur a one-time restructuring charge of approximately $1.1 million that will be recorded in the fourth quarter of 2023. We expect our 2023 net cash burn to range between $90 million to $95 million, excluding any proceeds received from our at-the-market offering program. Importantly, we believe our cash runway will be sufficient to now fund our operations into the first quarter of 2026. In closing, we have a strong financial position to advance our mission, and we remain committed to developing our HBV assets to provide a functional cure for chronic HBV. With that, I will now turn the call back to Bill.

Thanks, Dave. As I mentioned earlier, we're looking forward to reporting preliminary data from the AB-729-202 Phase 2a study combining imdusiran, NUC therapy and VTP-300 at the AASLD liver meeting in the coming weeks. Immediately following that medical congress, we'll be attending the Jeffries Healthcare Conference in London. So please reach out to Lisa if you want to schedule time to meet with the team to review that data. In closing, I wish the best to our departing employees, and again, thank them for their dedication and many contributions to the company as we continue to pursue our goal of developing a functional cure for patients with chronic HBV. Operator, we're now ready to open the call for any Q&As.

Thank you. At this time, we will conduct the question-and-answer session. [Operator Instructions] Our first question comes from Roy Buchanan for JMP. Your line is now open.

Hi. Great. So congrats to Bill for the retirement just as things are getting exciting over there and congrats to Mike for the promotion. I guess maybe if you will start with AB-101, just the results in the first half of next year. Are you going to have, sounds like maybe not, but the complete SAD results and maybe just give us some patient number details if you can. And then are you going to share the data regularly with the FDA or are you going to wait to complete the whole Phase 1? And then just remind us what other activities like preclinical studies are underway with 101.

Okay, Roy. Thank you. Thank you for your well wishes. I'll turn it over to Karen in a moment. Maybe the best thing we could do to answer your question is just to describe the structure of the 101 Phase 1a study. I think I misspoke earlier on when I said it was a double-blind randomized study. So Karen, perhaps you could clarify that and answer Roy's question.

Absolutely. So I should know, Bill, you were correct. It is a double-blind randomized clinical trial. So it is a, what we call an umbrella trial. So there are healthy subject portions of the trial and chronic hepatitis B patient portions of the trial. So we begin in single ascending dose and healthy subjects and then move to multiple dose and healthy subjects and then on to chronic hepatitis B patients. So the way these trials run, you obviously need data from each part of the trial to advance to the next part of the trial. So right now, as Bill said, we're in the single ascending dose portion of the trial. We do expect to have data next year. It really depends on the cadence of the trial. If things continue to move smoothly, we recruit our subjects in a timely manner. So we should have some safety data, some PK data, some preliminary pharmacodynamic data in the first half of the year for the single dose portion of the trial in healthy subjects. Beyond that, it really just depends again on the cadence of the trial, the recruitment, and we will disclose data once we have a meaningful data package to report.

Okay, great. And then maybe what other activities are you doing? Some preclinical studies or anything that's underway with this one-on-one?

Mike, do you want to take that one?

Well, the standard non-clinical safety studies continue to move forward with 101. I think we've established a pretty solid package of data, preclinical data that supports the mechanism, which is novel, which supports efficacy in animal models. And obviously, ideal PK profile, which is liver targeting for this agent. But really, right now, the only activities is all the non-clinical toxicology assessments that are required to support further progression of the drug.

Okay, great. One more detailed question. Just in the inducer end studies, how frequently do you check for seroconversion of S antigen? And then on that really crystal ball or speculative question, have you guys ever considered hepatitis delta? Some of your competitors are using the same agents for hepatitis B and potential hepatitis delta. Have you considered that indication? And just what are your thoughts around that? Thanks.

So Karen, do you want to take the first part and then Mike the second?

Absolutely. So we are checking frequently in all of our clinical trials for surface antigen loss and seroconversion. The timing really depends on how the clinic visits were set up for subjects. So typically, whenever there's a clinic visit for a subject, we do collect those parameters just for monitoring. So it can vary anywhere from every month to every eight weeks, depending on where the subject is in the clinical trial, whether they're in the dosing phase and the follow-up phase. So we do collect those parameters at pretty much every study visit. And I would say ballpark every month, if not more frequent.

Yes, Roy. On the deltas question, yes, look, we've looked at a lot of targets. And delta was clearly one of them. The idea initially was that potentially one could use AB-729 as an siRNA to knock down antigen load or that it's required for delta to exist. Recent clinical data certainly has the generated data that's not supportive of that. There seems to be some liver safety issues associated with potentially the accumulation of delta-related antigens in the cell and, therefore, some significant ALT elevation. So our assessment is that a siRNA developed for hepatitis B is probably not an option for delta. So also, as Bill has mentioned, the focus, our efforts with our reduced headcount on hepatitis B, we still think that's a significant challenge that needs to be overcome. And we believe in our strategies. So that's where we're focusing our efforts.

Got it. Thank you.

Thank you, Roy.

Thank you. And one moment for our next question. Our next question comes from Dennis Ding of Jefferies. Your line is now open.

Hi, good morning. This is Anthea [Ph] on for Dennis. Two questions from us. What are your thoughts on GSK in licensing the J&J siRNA? And what does that mean for the hep B space? Was Arbutus also in discussions with GSK? And then second, could you comment on the LNP litigation and what we should expect heading into the joint construction brief in December? Thank you.

Yes, so let me take the second part first. And then maybe Mike Mack can talk about our business development efforts. So on the litigation front, as I think we put in the press release, there's no new news to announce. We continue to remain passionate about defending our patents. In the Moderna case, there is a claims construction meeting scheduled for February 7th. Right. So that's the next kind of data point in the Moderna trial. In the Pfizer case, there is not yet a date set for claims construction. I think that's about all we can say at this stage. So Mike, do you want to take the GSK news?

Business development questions? So I think the way we look at the GSK news is that any consolidation in the field, any licenses that happen in the hepatitis B space are good for the field generally. And of course, we want to see success in the hepatitis B space with people getting to functional cure. That's opportunity for everybody. So as you know, it's a very, very large market and can certainly support multiple competitors. With regards to conversations with any particular company, we can't comment on that, obviously. But I think it's fair to say that we stay closely in touch with everyone in the field. And we continue those conversations whenever appropriate.

Great. Thank you so much.

Thank you. And one moment for our next question. Our next question comes from Brian Skorney of Baird. Your line is now open.

Hey, guys. This is Charlie [Ph] on for Brian. Thanks for taking our questions. So one is you mentioned that with the reduction in force, the cash runway is extended through 2026. And I was just hoping you could contextualize this for us with your kind of ideal clinical development timeline and possibly other scenarios just to kind of get a better grasp on what this cash runway means for you and your development efforts, as well as could you do, based on your research, just a little bit of comparing and contrasting, following up on the recent question about the GSK deal with the asset that they just in-licensed compared to inducer-owned banks?

Yes. Okay. So, I mean, I think we're pleased that we've now extended the runway into 2026. It allows us, a good, clear two years' worth of funding. And as we continue to progress the Phase 2a studies, we'll get further readouts, further data readouts, and then that will inform the next phase of either Phase 2b or Phase 3. It's also going to allow us to continue to progress AB-101 through its Phase 1 activities. So all of that I think is quite encouraging. On the GSK question, a couple of comments. I think, one, it's another recognition of the fact that combination therapy is the way to go in hepatitis B. As far as comparing imdusiran with the asset that they've licensed in, I think there are a couple of key differences. As I mentioned in my comments earlier on, 729 has shown activity on all three of the components we believe are necessary for a functional cure, reducing HBV DNA, reducing surface antigen, and reawakening the immune system. And 729 is the only RNAi that's generated data showing dosage intervals of either monthly, every eight weeks, or every 12 weeks. So we have, built in some dosage flexibility moving forward. And then, Mike, you might want to just comment upon the single trigger aspect and any of the preclinical differences.

Yes, so preclinically, if you look at imdusiran, right, it's a single trigger agent, which cannot get all viral transcripts with one siRNA, including integrated transcripts that comes off of the host genome. One of the challenges with the J&J asset is that it requires two siRNAs to be able to accomplish what we're able to accomplish with one. So I think there's a big difference in when you look at cost of goods and feasibility of commercialization of those two different assets. They were a lower dose than they are as well. So there is, I think, a differentiating profile for imdusiran versus the J&J siRNA.

Great, thank you. That's very helpful.

Thank you, and one moment for our next question. Our next question comes from Thomas Yip of H.C. Wainwright. Your line is now open.

Hi, good afternoon, everyone. Good morning. Sorry about that. Thank you for taking our questions. Asking a couple of questions for us. First of all, I just want to say, Bill, Pat and I both have the honor of working with you and best of luck in your future endeavors. And, yes it's kind of close by surprise. But first, perhaps the first question from the extended cohort, from the Q2 study, the one with low dose nivolumab. Perhaps can you provide more specific timeframe for this preliminary readout? Should we expect something in the first half of the year? And then also, how many weeks of treatment data can we expect from this preliminary data set?

All right. Thomas, thank you very much for your well wishes. I appreciate that. Yes, so this additional arm that we've included in the 202 study that includes Nivo, obviously we announced that, a good time after we started the original study design. So it is running on a later time track. As we've announced, we have started dosing in that arm. So that arm is underway. We've not yet disclosed when we're likely to get data from that specific arm. I mean, I would point to the fact that most years, we normally do a press release with our kind of expectations early in January, and that might be another time to ask you a question

Got it. And then perhaps pertaining to this preliminary rate. Can you discuss what would be your seg a point that you will consider to be a successful trend.

Karen?

Sure absolutely. So as we've discussed, our goal certainly is to look for functional cure and hepatitis speed, certainly, there'll be interim steps readouts that will have to be taken before we get subjects to functional cures. So for this particular data set contains be looking at surface antigen decline based on the industry and leading period, which is 24 weeks of reduced treatment prior to remeasure either the VTP-300 immunotherapeutic or placebo. So certainly looking for imdusiran contribution to lower surface antigen during this lead-in period and then certainly, any impact to that VTP-300 has in terms of maintaining that service management decline, increasing that surface antigen decline and certainly anything related to additional immunomodulatory impacts in addition to what we have served previously with imdusiran on its own. So I think those are what we'll be looking for in this data readout that's coming up at ASLD unfortunately, still under embargo, so I can't share any of the details of that. But to be disclosed in the next few days as the conference begins.

Okay. Perhaps just 1 more question from us for AB-101 can you talk about how far and long the enrollment for each of the 3 parts? And if especially data for the third quarter in patients at data positive any possibility to those 101 combination with imdusiran as we have seen in the expansion cohort?

Yes. I think what we said so far in that study is that we'll have some initial data in the first half of next year. I think Karen also mentioned earlier on is still somewhat dependent upon recruitment rates into each of those arms. You're right that our ultimate aim would be to combine 1709 and 101 with the nuclear side. But we've not yet provided any time lines for that.

Okay, understand. Thank you for taking our questions. And we’re looking forward to the [Indiscernible].

Thank you.

Thank you. And this concludes the question-and-answer session. I would now like to turn it back to management for closing remarks.

Okay. Well, look, thank you very much, everyone, for joining us this morning. We appreciate your continued interest in and support of Arbutus and your questions. We very much look forward to providing you updates as we progress the development of our HBV clinical stage assets over coming months. So operator, that concludes our call for this morning.

Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.